Aldeyra Therapeutics Announces that Post-Hoc Analysis Using Computer Automated Grading of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap Over Vehicle for Primary Endpoint of Ocular Redness

Post-Hoc Analysis Using Computer Automated Grading Indicated that Reproxalap is Statistically Superior to Vehicle (p=0.020) in Reducing Dry-Eye Associated Ocular Redness, the Primary Endpoint of Phase 3 TRANQUILITY Trial Statistical Superiority of Reproxalap over Vehicle (p=0.003) for the Primary Endpoint of Ocular Redness in the Previously Announced Phase 2 Dry Eye Chamber Trial Confirmed Using … [Read more…]

RenovoRx to Participate in Upcoming H.C Wainwright Global Investment Conference in May 2022

LOS ALTOS, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced management’s participation in the H.C. Wainwright Global Investment Conference on May 23-26, 2022 in Miami Beach, Florida. H.C. Wainwright Global Investment Conference Format and Dates: Hybrid, May 23-26, 2022 Location: Fountainebleau Miami Beach … [Read more…]

LifeWorks declares May 2022 cash dividend

TORONTO–(BUSINESS WIRE)–(TSX: LWRK) LifeWorks Inc. (the “Company” or “LifeWorks”) announced today a cash dividend of $0.065 per share for the month of May 2022, to be paid on June 15, 2022 to holders of record of shares of LWRK on May 31, 2022. LifeWorks designates this dividend to be an “eligible dividend” pursuant to subsection … [Read more…]

Anji Pharma Completes Patient Enrollment in Phase 2 Study of Pradigastat in Functional Constipation

CAMBRIDGE, Mass. & SHANGHAI–(BUSINESS WIRE)–Anji Pharma, an emerging global medicines company, today announced it has completed enrollment in its Phase 2 proof of concept study of pradigastat (ANJ908), a diacylglycerol acyltransferase 1 (DGAT1) inhibitor, in patients with functional constipation. The trial is being conducted in five clinical sites in the U.S. and 20 clinical sites … [Read more…]

EpiEndo: Successful Completion of Phase I Study for Lead Asset EP395

First non-antibiotic macrolide to go into clinical development – targeting COPD Safety, tolerability and pharmacokinetic endpoints met Phase II planning underway REYKJAVIK, Iceland–(BUSINESS WIRE)–EpiEndo Pharmaceuticals (‘EpiEndo’), the clinical-stage biopharmaceutical company developing disease-modifying therapeutics for chronic respiratory disorders, has completed its Phase I First Time in Human (FTIH) study with EP395 in healthy subjects. EP395, is … [Read more…]

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference

LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will participate in a virtual fireside chat during the H.C. Wainwright Global Investment Conference, … [Read more…]

Bicara Therapeutics to Present Clinical Data from Lead Bifunctional Antibody Program, BCA101, at ASCO 2022 Annual Meeting

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to elicit a potent and durable immune response in the tumor microenvironment, today announced that it will present updated data from the dose escalation phase of its ongoing Phase 1 trial of BCA101, a bifunctional antibody designed to target the TGF-β trap to … [Read more…]

METiS Joins the Roche Accelerator

CAMBRIDGE, Mass.–(BUSINESS WIRE)–METiS today announced officially joining the Roche Accelerator with the goal to tap into Roche’s global scientific expertise, laboratory facilities and foster collaboration discussions on formulation development and optimization with Roche Innovation Center Shanghai. “We are excited to become a member of the Roche Accelerator and to establish a closer connection with a … [Read more…]

WellAir Brings Clean Air Technology to Brandywine Realty Trust Properties

Brandywine’s premier properties have implemented WellAir’s portfolio of IAQ solutions in elevators and select conference rooms to help improve and protect their indoor environments. STAMFORD, Conn.–(BUSINESS WIRE)–WellAir, a leading provider of indoor air disinfection and purification solutions, today announced the implementation of its solutions in the elevator cabs throughout Brandywine’s entire Trophy Class of buildings … [Read more…]

Dr. Cheryl Renz Joins Pregistry as Chief Medical Officer

Pregistry’s Latest Recruitment Brings Senior Executive Talent to the Team LOS ANGELES–(BUSINESS WIRE)–#CMO—Pregistry, a leader in the development and conduct of observational studies during pregnancy, announced today the appointment of Dr. Cheryl Renz as the company’s Chief Medical Officer (CMO). In this role, Dr. Renz will oversee medical and pharmacovigilance strategies for the rapidly growing … [Read more…]